Right now, public doubt in American infant formula is high. In the last six months, there’s been more high-profile recalls in the industry globally than in the last six years, with unprecedented foodborne illnesses directly impacting infants. But the reality is that this is not a uniquely American problem. These vulnerabilities are impacting the industry globally. However, America is well positioned to do something about it.

What I know to be true: An industry that feeds babies must be an industry of absolute transparency. We have nothing to hide, and everything to protect.

When I founded Bobbie eight years ago, I was a newcomer trying to navigate a highly consolidated, decades-old market. For years, the public was led to believe that infant formula manufacturing had to look a certain way. We inherited a legacy framework shaped by giants before us, and we respect that heritage deeply. But respecting heritage does not mean standing still. Evolution is required at every turn.

Today, Bobbie is no longer the new player. We are proudly one of only four domestic infant formula manufacturers in the U.S., anchored by our own state-of-the-art facility in Heath, Ohio. Since 2021, we have safely nourished more than one million American babies. Out of those four domestic manufacturers, Bobbie stands alone as the only one founded, owned, and led by a woman and a mother.

That reality changes how you build a business, and it dictates how you manage risk.

The hardest, most sobering truth of food manufacturing is that no company, regardless of size, history, or capital, is inherently immune to risk. The global supply chain is complex, and biological risks are real. Acknowledging that isn't a defensive shrug; it is our daily operational mandate that deserves to be addressed.

Yet, the real risk to American families right now is standing still. As lawmakers respond to industry crises, we are seeing new safety bills that would place additional responsibilities onto individual manufacturers. While well-intentioned, this is only the start. We don’t simply need “more testing,” we need to set federal action limits established by the FDA. But that’s only one piece of the puzzle. What we’re fundamentally missing is an evolution toward a true culture of quality and safety, where regulators and manufacturers act as partners with shared accountability.

True prevention means building an open-door policy with the FDA. It means proactively sharing samples, disclosing vulnerabilities before they become crises, and ensuring the FDA is properly resourced, staffed, and expert-equipped to drive this industry forward. A framework built on communication and shared data would allow us to anticipate what could be, rather than reacting to the bacteria that hit months ago. 

Take a real-world example of how this should work: When new information emerges that a specific raw ingredient or supply chain could be a carrier for a unique toxin, like Clostridium botulinum in whole milk powder, the standard industry response shouldn’t be to cross our fingers and wait for a regulatory body to force our hand. The immediate, responsible action must be to pause, evaluate that supply chain, and work toward a long-lasting solution.

That is exactly the action we took at Bobbie. We didn't wait for a new federal mandate to catch up to the science. Instead, we immediately added an entirely new testing layer on top of our existing pre- and post-production protocols specifically designed to target Clostridium botulinum in our whole milk powder supply chain. 

The solution to industry fragility is not to shrink back, nor is it to consolidate into the monopolies of the past. We do not need fewer players in the infant formula space; we need a dynamic, resilient marketplace driven by a culture of unyielding safety, state-of-the-art testing, advanced technology that connects regulators to ongoing reporting, and diverse supply chains.